These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32032241)

  • 1. Cell-free DNA Oncogene Copy Number as a Surrogate Molecular Biomarker in ALK/MYCN-coamplified Neuroblastoma.
    Kobayashi K; Mizuta S; Yamane N; Hamabata T; Maihara T; Usami I; Heike T
    J Pediatr Hematol Oncol; 2021 Mar; 43(2):e165-e168. PubMed ID: 32032241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Detection of Copy Number Variations of MYCN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma.
    Trivedi T; Panchal K; Bhalala N; Trivedi P; Panchal H
    World Neurosurg; 2022 Mar; 159():e48-e57. PubMed ID: 34861448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction.
    Peitz C; Sprüssel A; Linke RB; Astrahantseff K; Grimaldi M; Schmelz K; Toedling J; Schulte JH; Fischer M; Messerschmidt C; Beule D; Keilholz U; Eggert A; Deubzer HE; Lodrini M
    J Mol Diagn; 2020 Nov; 22(11):1309-1323. PubMed ID: 32858250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
    Marrano P; Irwin MS; Thorner PS
    Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
    Nakazawa A
    Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assessment of copy number alterations by liquid biopsy for neuroblastoma.
    Shirai R; Osumi T; Sato-Otsubo A; Nakabayashi K; Ishiwata K; Yamada Y; Yoshida M; Yoshida K; Shioda Y; Kiyotani C; Terashima K; Tomizawa D; Takasugi N; Takita J; Miyazaki O; Kiyokawa N; Yoneda A; Kanamori Y; Hishiki T; Matsumoto K; Hata K; Yoshioka T; Kato M
    Genes Chromosomes Cancer; 2022 Nov; 61(11):662-669. PubMed ID: 35655408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and Prognostic Impact of
    Bellini A; Pötschger U; Bernard V; Lapouble E; Baulande S; Ambros PF; Auger N; Beiske K; Bernkopf M; Betts DR; Bhalshankar J; Bown N; de Preter K; Clément N; Combaret V; Font de Mora J; George SL; Jiménez I; Jeison M; Marques B; Martinsson T; Mazzocco K; Morini M; Mühlethaler-Mottet A; Noguera R; Pierron G; Rossing M; Taschner-Mandl S; Van Roy N; Vicha A; Chesler L; Balwierz W; Castel V; Elliott M; Kogner P; Laureys G; Luksch R; Malis J; Popovic-Beck M; Ash S; Delattre O; Valteau-Couanet D; Tweddle DA; Ladenstein R; Schleiermacher G
    J Clin Oncol; 2021 Oct; 39(30):3377-3390. PubMed ID: 34115544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
    Yagyu S; Iehara T; Tanaka S; Gotoh T; Misawa-Furihata A; Sugimoto T; London WB; Hogarty MD; Teramukai S; Nakagawara A; Hiyama E; Maris JM; Hosoi H
    PLoS One; 2016; 11(8):e0161039. PubMed ID: 27513929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
    Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
    J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.
    Kim EK; Kim S
    Pediatr Dev Pathol; 2017; 20(2):133-141. PubMed ID: 28326957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
    Bagci O; Tumer S; Olgun N; Altungoz O
    Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.
    Bobin C; Iddir Y; Butterworth C; Masliah-Planchon J; Saint-Charles A; Bellini A; Bhalshankar J; Pierron G; Combaret V; Attignon V; André N; Corradini N; Dumont B; Mansuy L; Khanfar C; Klein S; Briandet C; Plantaz D; Millot F; Thouvenin S; Aerts I; Ndounga-Diakou LA; Laghouati S; Abbou S; Jehanno N; Tissot H; Renault S; Baulande S; Raynal V; Bozec L; Bieche I; Delattre O; Berlanga P; Schleiermacher G
    Clin Cancer Res; 2024 Aug; 30(15):3316-3328. PubMed ID: 38787533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma.
    Somasundaram DB; Aravindan S; Gupta N; Yu Z; Baker A; Aravindan N
    World J Pediatr; 2022 Apr; 18(4):285-293. PubMed ID: 35132576
    [No Abstract]   [Full Text] [Related]  

  • 14. ALK positively regulates MYCN activity through repression of HBP1 expression.
    Claeys S; Denecker G; Durinck K; Decaesteker B; Mus LM; Loontiens S; Vanhauwaert S; Althoff K; Wigerup C; Bexell D; Dolman E; Henrich KO; Wehrmann L; Westerhout EM; Demoulin JB; Kumps C; Van Maerken T; Laureys G; Van Neste C; De Wilde B; De Wever O; Westermann F; Versteeg R; Molenaar JJ; Påhlman S; Schulte JH; De Preter K; Speleman F
    Oncogene; 2019 Apr; 38(15):2690-2705. PubMed ID: 30538293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Targeting of
    Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK Gene Mutation and ALK Protein Expression in Advanced Neuroblastoma and the Potential Value in Risk Stratification in Fine-Needle Aspiration Biopsy Samples.
    Bhardwaj N; Rohilla M; Gautam U; Trehan A; Bansal D; Kakkar N; Srinivasan R
    Am J Clin Pathol; 2023 Apr; 159(4):407-415. PubMed ID: 36812383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma.
    Lodrini M; Graef J; Thole-Kliesch TM; Astrahantseff K; Sprüssel A; Grimaldi M; Peitz C; Linke RB; Hollander JF; Lankes E; Künkele A; Oevermann L; Schwabe G; Fuchs J; Szymansky A; Schulte JH; Hundsdörfer P; Eckert C; Amthauer H; Eggert A; Deubzer HE
    Clin Cancer Res; 2022 May; 28(9):1809-1820. PubMed ID: 35247920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma.
    Kojima M; Hiyama E; Fukuba I; Yamaoka E; Ueda Y; Onitake Y; Kurihara S; Sueda T
    Pediatr Surg Int; 2013 Nov; 29(11):1139-45. PubMed ID: 24022278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.
    Somasundaram DB; Aravindan S; Yu Z; Jayaraman M; Tran NTB; Li S; Herman TS; Aravindan N
    BMC Cancer; 2019 Jan; 19(1):106. PubMed ID: 30691436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic roles of and correlation between
    Chang HH; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Hsu WM; Jeng YM; Jou ST
    J Clin Pathol; 2020 Mar; 73(3):154-161. PubMed ID: 31542727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.